Back to Search
Start Over
Novel antibodies against follicular non-Hodgkin’s lymphoma.
- Source :
- Best Practice & Research: Clinical Haematology; Jun2011, Vol. 24 Issue 2, p231-256, 26p
- Publication Year :
- 2011
-
Abstract
- The anti-CD20 monoclonal antibody rituximab has revolutionized the treatment of patients with follicular B-cell lymphoma. With the combination of chemotherapy and rituximab the overall survival rate has increased with approximately 30%. Unfortunately, there is resistance to rituximab with relapse of the disease in about 60% of the patients during the first five years of treatment and eventually in all patients. To this end, there is a need to develop improved anti-CD20 monoclonal antibodies and antibodies that target other attractive molecules expressed on the follicular lymphoma cell. This review describes the development and clinical achievements so far of next generation anti-CD20 and other antibodies in the treatment of follicular B-cell lymphoma. [Copyright &y& Elsevier]
Details
- Language :
- English
- ISSN :
- 15216926
- Volume :
- 24
- Issue :
- 2
- Database :
- Supplemental Index
- Journal :
- Best Practice & Research: Clinical Haematology
- Publication Type :
- Academic Journal
- Accession number :
- 61248689
- Full Text :
- https://doi.org/10.1016/j.beha.2011.03.002